World Health Organization site
Skip Navigation Links

Main
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register.
Register: ClinicalTrials.gov
Last refreshed on: 18 October 2021
Main ID:  NCT02649218
Date of registration: 15/12/2015
Prospective Registration: Yes
Primary sponsor: Novartis Pharmaceuticals
Public title: A Safety Extension Study to Evaluate the Long-term Safety of QGE031 in Chronic Spontaneous Urticaria (CSU) Patients
Scientific title: An Open Label, Multicenter, Extension Study to Evaluate the Long-term Safety of QGE031 240 mg s.c. Given Every 4 Weeks for 52 Weeks in Chronic Spontaneous Urticaria Patients Who Completed Study CQGE031C2201
Date of first enrolment: May 24, 2016
Target sample size: 226
Recruitment status: Completed
URL:  https://clinicaltrials.gov/show/NCT02649218
Study type:  Interventional
Study design:  Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).  
Phase:  Phase 2
Countries of recruitment
Australia Canada Germany Greece Japan Russian Federation Spain Taiwan
United Kingdom United States
Contacts
Key inclusion & exclusion criteria

Inclusion Criteria:

- Patients eligible for inclusion in this study have to fulfill all of the following
criteria:

1. Written informed consent must be obtained before any assessment is performed.

2. Patients who complete the treatment epoch in study CQGE031C2201 and complete at
least Visit 203 (Week 32 of the follow-up epoch, =16 weeks after last injection)
and present with active disease as defined by UAS7 =12.

3. Patients must not have any missing eDiary entries in the 7 days prior to Visit
301 (patients are allowed to repeat until this criterion is met).

4. Willing and able to complete a daily symptom eDiary for the duration of the study
and adhere to the study visit schedules.

Exclusion Criteria:

Clearly defined underlying etiology for chronic urticaria other than chronic spontaneous
urticaria

- Evidence of parasitic infection

- Any other skin diseases than chronic spontaneous urticaria with chronic itching

- Contraindications to or hypersensitivity to fexofenadine, loratadine, cetirizine, or
epinephrine

- History of anaphylaxis

- History or current diagnosis of ECG abnormalities indicating significant risk of
safety for patients participating in the study

- History of hypersensitivity to any of the study drugs or its components of similar
chemical classes

- Pregnant or nursing (lactating) women Other protocol-defined inclusion/exclusion
criteria may apply



Age minimum: 18 Years
Age maximum: 75 Years
Gender: All
Health Condition(s) or Problem(s) studied
Chronic Spontaneous Urticaria
Intervention(s)
Biological: Ligelizumab
Primary Outcome(s)
Number of Participants With at Least One Treatment Emergent Adverse Event (AE) [Time Frame: Within 16 weeks after Week 48]
Secondary Outcome(s)
Percentage of Subjects Having Achieved UAS7 = 6 [Time Frame: Baseline, Week 52 and Week 100]
Number and Proportion of Participants Who Achieved UAS7= 6 [Time Frame: Baseline, Week 52, Week 100]
Secondary ID(s)
CQGE031C2201E1
2015-003636-13
Source(s) of Monetary Support
Please refer to primary and secondary sponsors
Secondary Sponsor(s)
Ethics review
Results
Results available: Yes
Date Posted: 14/08/2020
Date Completed:
URL: https://clinicaltrials.gov/ct2/show/results/NCT02649218
Disclaimer: Trials posted on this search portal are not endorsed by WHO, but are provided as a service to our users. In no event shall the World Health Organization be liable for any damages arising from the use of the information linked to in this section. None of the information obtained through use of the search portal should in any way be used in clinical care without consulting a physician or licensed health professional. WHO is not responsible for the accuracy, completeness and/or use made of the content displayed for any trial record.
Copyright - World Health Organization - Version 3.6 - Version history